NOVO NORDISK A/S |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 883.2 DKK | +0.07% |
|
-1.62% | +26.51% |
| 07:03am | Europe's laggard stocks sparkle as superstars hit pause | RE |
| May. 08 | NOVO NORDISK : Berenberg reiterates its Neutral rating | ZD |
ETFs positioned on Novo Nordisk A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.56% | 1,166 M€ | +0.26% | - | |
| 0.56% | 607 M€ | +0.05% | - | |
| 0.47% | 205 M€ | -.--% | ||
| 0.43% | 0 M€ | +7.45% | ||
| 0.39% | 0 M€ | +17.73% | ||
| 0.29% | 0 M€ | +8.21% | - | |
| 0.26% | 0 M€ | 0.00% | - | |
| 0.24% | 0 M€ | +7.83% | - | |
| 0.18% | 0 M€ | +5.54% | - | |
| 0.18% | 0 M€ | +5.36% | - | |
| 0.17% | 0 M€ | +0.99% | - | |
| 0.15% | 0 M€ | +3.32% | - | |
| 0.13% | 0 M€ | +3.45% | - | |
| 0.12% | 0 M€ | +2.51% | - | |
| 0.09% | 0 M€ | +3.09% | - |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.51% | 568B | |
| +32.95% | 698B | |
| -4.97% | 358B | |
| +18.83% | 328B | |
| +3.54% | 283B | |
| +15.69% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +6.70% | 165B | |
| -1.81% | 160B |
- Stock Market
- Equities
- NOVO B Stock
- Funds and ETFs Novo Nordisk A/S